ecotropic viral integration site 5Genealiases: EVI-5 · NB4S
Q-omics provides the consensus-scored EVI5 profile across patient tissues and cancer cell-line models. EVI5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, EVI5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, EVI5 RNA expression shows 20,632 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where EVI5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EVI5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EVI5 survival associations across molecular data types. EVI5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EVI5 RNA expression–survival associations across cancer types. High EVI5 expression shows unfavorable associations in KICH, BLCA, LGG, LUSC and MESO, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for EVI5 RNA expression.
This table summarizes EVI5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for EVI5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EVI5 shows lower tumor expression in LUSC, KICH, LUAD, UCEC and THCA and higher tumor expression in HNSC. The HNSC box plot shows higher EVI5 RNA expression in tumor versus normal tissue (log2 FC = +0.370, t-test p < 0.001).
This table shows molecular features associated with EVI5 in patient tissues and cancer cell lines. In patient samples, EVI5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EVI5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
